Edwards(US:EW) GlobeNewswire News Roomยท2024-10-21 11:45Core Viewpoint - A securities fraud class action lawsuit has been filed against Edwards Lifesciences Corporation, alleging misrepresentations related to its Transcatheter Aortic Valve Replacement platform and market demand [2]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Central District of California on behalf of investors who purchased Edwards securities between February 6, 2024, and July 24, 2024 [2]. - Allegations include violations of the Securities Exchange Act of 1934, with claims that Edwards misrepresented its commitment to the Transcatheter Aortic Valve Replacement platform and its ability to engage untreated patients [2]. Group 2: Legal Representation and Actions - Investors wishing to serve as lead plaintiffs must file necessary documents by December 13, 2024, although participation as a class member does not require this [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [3].